Dipeptidyl peptidase IV (DPP IV) inhibitors: A newly emerging drug class for the treatment of type 2 diabetes.
Dipeptidyl peptidase IV (DPP IV) inhibitors: A newly emerging drug class for the treatment of type 2 diabetes.
复制标题
DOI：
10.3132/dvdr.2006.024
复制
发表时间：
2006-12-01
影响因子：
2.4
通讯作者：
Bailey, Clifford J
中科院分区：
文献类型：
--
作者：
Green, Brian D;Flatt, Peter R;Bailey, Clifford J
酶二肽基肽酶IV（DPP IV）的抑制剂提供了用于治疗2型糖尿病的策略。DPP IV可快速灭活肠促胰岛素激素胰高血糖素样肽-1（GLP-1）和葡萄糖依赖性促胰岛素多肽（GIP）。DPP IV的抑制可延长并增强内源性GLP-1和GIP的活性，这些物质是胰岛素分泌的重要餐时刺激物和血糖控制的调节剂。在临床试验中，DPP IV抑制剂（或“格列汀”）在2型糖尿病高血糖症的管理中显示出疗效和耐受性，而不会导致体重增加或低血糖。
Inhibitors of the enzyme dipeptidyl peptidase IV (DPP IV) provide a strategy for the treatment of type 2 diabetes. DPP IV rapidly inactivates the incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). Inhibition of DPP IV prolongs and enhances the activity of endogenous GLP-1 and GIP, which serve as important prandial stimulators of insulin secretion and regulators of blood glucose control. In clinical trials DPP IV inhibitors (or 'gliptins') have shown efficacy and tolerability in the management of hyperglycaemia in type 2 diabetes, without causing weight gain or hypoglycaemia.